DexCom, Inc. (DXCM) Up 4.7% — Is This Setup Too Good to Pass Up?
DexCom, Inc. (DXCM) is gaining ground in Thursday's session, last trading at $87.35 on the NASDAQ, a $3.88 gain from the prior close of $83.47. The advance puts the stock within striking distance of its 52-week high of $92.59, set on August 24, 2026. At the current quote, DXCM sits roughly 5.7% below that peak, and today's move recovers a meaningful share of the ground lost since late summer.
Volume stood at approximately 852,873 shares at the time of the quote, against a 90-day average of roughly 4.57 million. With the regular session still open, turnover is tracking well below a full day's typical pace even as buyers lift the price.
Why DexCom, Inc. Price is Moving Higher
The catalyst is clinical and specific to the company. On October 14, Dexcom announced that its CONNECT trial had been published in The New England Journal of Medicine. The study enrolled adults with type 2 diabetes who do not use insulin. Dexcom G7 users saw their average A1C fall 1.6% from a baseline of 8.8%, a 0.9% greater reduction than patients on routine care. They also spent about five more hours per day in the target glucose range. Publication in the most prominent medical journal gives the data immediate credibility with physicians and payers. It also strengthens the case for using continuous glucose monitoring earlier in type 2 treatment, a patient population far larger than the insulin-dependent base that has historically driven CGM adoption.
The commercial implication is what has investors leaning in. These results could support broader Medicare coverage for non-insulin type 2 patients. No coverage decision has been made, but the evidence now gives Dexcom a peer-reviewed argument to make. The broader Health Care group is also firm today. UnitedHealth Group Incorporated (UNH) is up 3.40%, and Abbott Laboratories (ABT), Dexcom's chief CGM rival, is up 2.43%. DXCM's 4.65% gain outpaces both, which marks this as a stock-specific rally on its own data rather than a passive ride on sector strength.
The fundamental foundation supports the enthusiasm. Dexcom's Q2 report on July 30 showed adjusted EPS of $0.70 against a $0.61 estimate, a clean beat. Revenue reached $1.31 billion versus $1.29 billion expected, up 13% year over year. Management raised its 2026 revenue guidance to between $5.18 billion and $5.25 billion, a signal of confidence in the growth trajectory. The next checkpoint is close: Dexcom reports Q3 results on October 29 after the market close. Today's clinical news gives that call a constructive backdrop.
What is the DexCom, Inc. Rating - Should I Buy?
Weiss Ratings assigns DXCM a C+ rating. Current recommendation is Hold. That places Dexcom at the upper edge of Hold territory. The business fundamentals are strong, and the stock's trading record is what keeps the rating out of Buy range for now.
The operating case is about as strong as it gets. Dexcom is rated Excellent on the Growth Index, Efficiency Index, and Solvency Index. The Growth Index rating reflects 13.08% revenue growth at a company already generating more than $5 billion in annual sales. Sustaining double-digit expansion at that scale signals that CGM adoption is still broadening rather than maturing. The Excellent Efficiency Index rating is backed by a 38.49% return on equity and a 20.11% profit margin. Those are standout figures for a medical device maker that must fund heavy R&D and large-scale sensor manufacturing. The Excellent Solvency Index rating rounds out the picture. Dexcom has the balance sheet to keep investing in new indications, such as the non-insulin type 2 market CONNECT targets, without financial strain.
Where the picture becomes more nuanced is in the market-based measures. Dexcom is rated Fair on the Total Return Index. That reflects a stock that has delivered uneven results for holders over the measurement period, even after recovering toward its $92.59 peak. The Weak Volatility Index reflects how sharply DXCM reprices on news. Today's 4.65% jump on a single journal publication shows how sensitive the shares are to clinical and reimbursement headlines. With a forward P/E of 32.95 and trailing EPS of $2.53, investors are paying for growth, and that premium can amplify swings in either direction. These two dimensions are why the overall rating holds at C+ rather than advancing into Buy territory.
Within the Health Care sector, DexCom sits alongside Medtronic plc (MDT, C+) and CVS Health Corporation (CVS, C+). It ranks ahead of Abbott Laboratories (ABT, C), Intuitive Surgical, Inc. (ISRG, C), and UnitedHealth Group Incorporated (UNH, C). Given that Abbott competes directly with Dexcom in glucose monitoring, Dexcom's edge in the Weiss framework stands out.
About DexCom, Inc.
DexCom, Inc. (DXCM) is a Health Care company and a pioneer in continuous glucose monitoring for people with diabetes. Founded in 1999 and headquartered in San Diego, California, the company designs, develops, and commercializes wearable biosensor systems. These systems track glucose levels in real time and send readings to smartphones, receivers, and connected insulin delivery devices. That lets patients and clinicians manage diabetes with far more precision than traditional fingerstick testing allows.
The flagship Dexcom G7 is the company's latest-generation sensor. It offers a smaller all-in-one wearable design, a faster warm-up period, and direct-to-phone connectivity. The Dexcom G6 remains in use across many markets. Dexcom ONE+ serves cost-sensitive international markets. Stelo, an over-the-counter biosensor, extends the company's reach to adults with type 2 diabetes who do not use insulin, the same population at the center of the CONNECT trial. Dexcom sensors also integrate with automated insulin delivery systems from partner pump makers. That makes Dexcom a core component of closed-loop diabetes management.
Dexcom's competitive advantages rest on sensor accuracy, a deep base of clinical evidence, broad reimbursement coverage, and a growing ecosystem of software and device integrations. Its data platforms give clinicians and patients actionable insights, which deepens engagement and reinforces recurring sensor revenue. The company's commercial reach spans the United States, Europe, and other international markets. As clinical guidelines increasingly favor earlier CGM use, Dexcom is positioned to expand well beyond its traditional insulin-using base.
Investor Outlook
DexCom, Inc. (DXCM) carries a Weiss Rating of C+ (Hold), and new NEJM-published evidence supporting CGM use in non-insulin type 2 diabetes gives the growth story a powerful new chapter. Investors should watch the October 29 Q3 report for progress against the raised $5.18 billion to $5.25 billion revenue guidance, along with any movement on Medicare coverage for the expanded patient population. See full rankings of all C+ rated Health Care stocks inside the Weiss Stock Screener.
--